Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 15Breast 7Thoracic 6Genitourinary 6Gastrointestinal 6Head & Neck 4Dermatologic 4Other solid neoplasm 3Sarcoma 2Endocrine 1CNS 1

Conditions

Sarcoma 22Melanoma 6Histiocytoma, Malignant Fibrous 6Gastrointestinal Stromal Tumors 5Osteosarcoma 4Neoplasm Metastasis 4Gliosarcoma 4Neuroblastoma 3Hemangiosarcoma 3Chordoma 3Bone Neoplasms 3Wilms Tumor 2Triple Negative Breast Neoplasms 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Lymphoma 2Lung Neoplasms 2Liver Neoplasms 2Liposarcoma 2Head and Neck Neoplasms 2Glioblastoma 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Bile Duct Neoplasms 2

Interventions

Filgrastim 14Cyclophosphamide 13Carboplatin 12Paclitaxel 8Ifosfamide 8Doxorubicin 8pembrolizumab 7Peripheral Blood Stem Cell Transplantation 6Gemcitabine 6fludarabine 5Temozolomide 5Specimen Handling 5Radiotherapy 5Cisplatin 5Magnetic Resonance Spectroscopy 4Etoposide 4Docetaxel 4Amifostine 4aldesleukin 3Trastuzumab 3Taxes 3Psychiatric Rehabilitation 3Melphalan 3Fulvestrant 3Bevacizumab 3sodium thiosulfate 2pazopanib 2pamiparib 2palbociclib 2etoposide phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Ipilimumab × Sarcoma × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Agenus Inc.

Phase 1 Active not recruiting
499 enrolled
GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡